Three-Year Change in Inflammatory Markers in Elderly People and Mortality: The Invecchiare in Chianti Study
Dawn E. Alley PhD
From the * Robert Wood Johnson Foundation Health and Society Scholars Program, University of Pennsylvania, Philadelphia, Pennsylvania † Davis School of Gerontology, University of Southern California, Los Angeles, California ‡ Department of Biostatistics, Bloomberg School of Public Health, the Johns Hopkins University, Baltimore, Maryland § Epidemiology, Demography, and Biometry Program, National Institute on Aging, Bethesda, Maryland ∥ Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, Maryland.
Search for more papers by this authorEileen Crimmins PhD
From the * Robert Wood Johnson Foundation Health and Society Scholars Program, University of Pennsylvania, Philadelphia, Pennsylvania † Davis School of Gerontology, University of Southern California, Los Angeles, California ‡ Department of Biostatistics, Bloomberg School of Public Health, the Johns Hopkins University, Baltimore, Maryland § Epidemiology, Demography, and Biometry Program, National Institute on Aging, Bethesda, Maryland ∥ Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, Maryland.
Search for more papers by this authorKaren Bandeen-Roche PhD
From the * Robert Wood Johnson Foundation Health and Society Scholars Program, University of Pennsylvania, Philadelphia, Pennsylvania † Davis School of Gerontology, University of Southern California, Los Angeles, California ‡ Department of Biostatistics, Bloomberg School of Public Health, the Johns Hopkins University, Baltimore, Maryland § Epidemiology, Demography, and Biometry Program, National Institute on Aging, Bethesda, Maryland ∥ Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, Maryland.
Search for more papers by this authorJack Guralnik MD, PhD
From the * Robert Wood Johnson Foundation Health and Society Scholars Program, University of Pennsylvania, Philadelphia, Pennsylvania † Davis School of Gerontology, University of Southern California, Los Angeles, California ‡ Department of Biostatistics, Bloomberg School of Public Health, the Johns Hopkins University, Baltimore, Maryland § Epidemiology, Demography, and Biometry Program, National Institute on Aging, Bethesda, Maryland ∥ Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, Maryland.
Search for more papers by this authorLuigi Ferrucci MD, PhD
From the * Robert Wood Johnson Foundation Health and Society Scholars Program, University of Pennsylvania, Philadelphia, Pennsylvania † Davis School of Gerontology, University of Southern California, Los Angeles, California ‡ Department of Biostatistics, Bloomberg School of Public Health, the Johns Hopkins University, Baltimore, Maryland § Epidemiology, Demography, and Biometry Program, National Institute on Aging, Bethesda, Maryland ∥ Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, Maryland.
Search for more papers by this authorDawn E. Alley PhD
From the * Robert Wood Johnson Foundation Health and Society Scholars Program, University of Pennsylvania, Philadelphia, Pennsylvania † Davis School of Gerontology, University of Southern California, Los Angeles, California ‡ Department of Biostatistics, Bloomberg School of Public Health, the Johns Hopkins University, Baltimore, Maryland § Epidemiology, Demography, and Biometry Program, National Institute on Aging, Bethesda, Maryland ∥ Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, Maryland.
Search for more papers by this authorEileen Crimmins PhD
From the * Robert Wood Johnson Foundation Health and Society Scholars Program, University of Pennsylvania, Philadelphia, Pennsylvania † Davis School of Gerontology, University of Southern California, Los Angeles, California ‡ Department of Biostatistics, Bloomberg School of Public Health, the Johns Hopkins University, Baltimore, Maryland § Epidemiology, Demography, and Biometry Program, National Institute on Aging, Bethesda, Maryland ∥ Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, Maryland.
Search for more papers by this authorKaren Bandeen-Roche PhD
From the * Robert Wood Johnson Foundation Health and Society Scholars Program, University of Pennsylvania, Philadelphia, Pennsylvania † Davis School of Gerontology, University of Southern California, Los Angeles, California ‡ Department of Biostatistics, Bloomberg School of Public Health, the Johns Hopkins University, Baltimore, Maryland § Epidemiology, Demography, and Biometry Program, National Institute on Aging, Bethesda, Maryland ∥ Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, Maryland.
Search for more papers by this authorJack Guralnik MD, PhD
From the * Robert Wood Johnson Foundation Health and Society Scholars Program, University of Pennsylvania, Philadelphia, Pennsylvania † Davis School of Gerontology, University of Southern California, Los Angeles, California ‡ Department of Biostatistics, Bloomberg School of Public Health, the Johns Hopkins University, Baltimore, Maryland § Epidemiology, Demography, and Biometry Program, National Institute on Aging, Bethesda, Maryland ∥ Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, Maryland.
Search for more papers by this authorLuigi Ferrucci MD, PhD
From the * Robert Wood Johnson Foundation Health and Society Scholars Program, University of Pennsylvania, Philadelphia, Pennsylvania † Davis School of Gerontology, University of Southern California, Los Angeles, California ‡ Department of Biostatistics, Bloomberg School of Public Health, the Johns Hopkins University, Baltimore, Maryland § Epidemiology, Demography, and Biometry Program, National Institute on Aging, Bethesda, Maryland ∥ Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, Maryland.
Search for more papers by this authorAbstract
OBJECTIVES: To describe changes in interleukin-6 (IL-6) and C-reactive protein (CRP) and to determine how changes are related to mortality in elderly people.
DESIGN: Prospective cohort study.
SETTING: Two communities in the Tuscany region of Italy.
PARTICIPANTS: Randomly selected residents aged 65 and older who participated in the first two waves of data collection (N=736).
MEASUREMENTS: Two serum measurements of IL-6 and CRP taken 3 years apart. Mortality was observed for the 3 years after the second measurement; 79 deaths were observed in 2,079 person-years.
RESULTS: Correlations indicated marginal to moderate stability in IL-6 and CRP, with clinical categories remaining relatively stable over time. Baseline levels were not related to mortality between follow-up Years 3 and 6, but increases in IL-6 and CRP predicted 3- to 6-year mortality. Controlling for follow-up IL-6 and CRP attenuated the relationship between inflammatory changes and mortality, but increases in CRP continued to increase odds of mortality. After controlling for sociodemographic characteristics, biological risk factors, health behaviors, and disease at both times, increases in CRP, but not IL-6, were related to mortality. Odds of death were more than three times as great in subjects in whom any CRP increase was observed (odds ratio=3.10, 95% confidence interval=1.25–7.68) as in subjects with stable or declining CRP.
CONCLUSION: CRP and IL-6 levels within individuals vary over time, and increases in CRP are associated with greater mortality risk. Three-year changes in inflammatory markers are better predictors of mortality than baseline measures.
REFERENCES
- 1 Fahdi IE, Gaddam V, Garza L et al. Inflammation, infection, and atherosclerosis. Brain Behav Immun 2003; 17: 238–244.
- 2 Cesari M, Penninx BWJH, Newman AB et al. Inflammatory markers and onset of cardiovascular events: The Health ABC Study. Circulation 2003; 108: 2317–2322.
- 3 Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analysis. BMJ 2000; 321: 199–204.
- 4 Ridker PM, Glynn RJ, Hennekens CH. CRP adds to the predictive value of total and HDL cholesterol in determining risk of first MI. Circulation 1998; 97: 2007–2011.
- 5 Harris TB, Ferrucci L, Tracy RP et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506–512.
- 6 Reuben DB, Cheh AI, Harris T et al. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc 2002; 50: 638–644.
- 7 Volpato S, Guralnik JM, Ferrucci L et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: The Women's Health and Aging Study. Circulation 2001; 103: 947–953.
- 8
Clark GH,
Fraser CG.
Biological variation of acute phase proteins.
Ann Clin Biochem
1993; 20: 373–376.
10.1177/000456329303000404 Google Scholar
- 9 Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387–1397.
- 10 Ho GYF, Xue X-N, Burk RD et al. Variability of serum levels of tumor necrosis factor-alpha, interleukin-6, and soluble interleukin 6 receptor over 2 years in young women. Cytokine 2005; 30: 1–6.
- 11 Koenig W, Sund M, Frohlich M et al. Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time. Am J Epidemiol 2003; 158: 357–364.
- 12 Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications. Clin Chem 1997; 43: 52–58.
- 13 Ockene IS, Matthews CE, Rifai N et al. Variability and classification of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001; 47: 444–450.
- 14 Rao KM, Pieper CS, Currie MS et al. Variability of plasma IL-6 and crosslinked fibrin dimers over time in community dwelling elderly subjects. Am J Clin Pathol 1994; 102: 802–805.
- 15 Ridker PM, Rifai N, Pfeffer MA et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230–235.
- 16 Ferrucci LF, Bandinelli S, Benvenuti E et al. Subsystems contributing to decline in ability to walk: Bridging the gap between epidemiology and geriatric practice in the InCHIANTI Study. J Am Geriatr Soc 2000; 48: 1618–1625.
- 17 Ferrucci L, Harris TB, Guralnik JM et al. Serum IL-6 level and the development of disability in older persons. JAMA 1999; 47: 639–646.
- 18 Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practices. Circulation 2003; 107: 499–511.
- 19 Ferrucci L, Corsi A, Lauretani F et al. The origins of age-related pro-inflammatory state. Blood 2005; 105: 2294–2299.
- 20 Alley D, Seeman TE, Kim JK et al. Socioeconomic status and C-reactive protein levels in the US population: NHANES IV. Brain Behav Immun 2006; 20: 498–504.
- 21 Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: The Third National Health and Nutrition Examination Survey. Arch Intern Med 2005; 165: 2063–2068.
- 22 Frohlich M, Sund M, Lowel H et al. Independent associations of various smoking characteristics with markers of systemic inflammation in men: Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003; 24: 1365–1372.
- 23 Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation 2003; 107: 443–447.
- 24 Pisani P, Faggiano F, Krogh V et al. Relative validity and reproducibility of a food frequency dietary questionnaire for use in the Italian EPIC centers. Int J Epidemiol 1997; 26: S152–S160.
- 25 Albert MA, Glynn RJ, Ridker PM. Effects of physical activity on serum C-reactive protein. Am J Cardiol 2004; 93: 221–225.
- 26 Reuben DB, Judd-Hamilton L, Harris TB et al. The associations between physical activity and inflammatory markers in high-functioning older persons: MacArthur studies of successful aging. J Am Geriatr Soc 2003; 51: 1125–1130.
- 27 Tilg H, Wilmer A, Vogel W et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264–274.
- 28 Pradhan AD, Manson JE, Rifai N et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J Am Med Assoc 2001; 286: 327–334.
- 29 Penninx BWJH, Kritchevsky SB, Yaffe K et al. Inflammatory markers and depressed mood in older persons: Results from the Health, Aging and Body Composition Study. Biol Psychiatry 2003; 54: 566–572.
- 30 Fava GA. Assessing depressive symptoms across cultures: Italian validation of the CES-D self-rating scale. J Clin Psychol 1983; 39: 249–251.
- 31 Jenny NS, Yanez ND, Psaty BM et al. Inflammation biomarkers and near-term death in older men. Am J Epidemiol 2007; 165: 684–695.
- 32 Walston J, McBurnie MA, Newman A et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities. Arch Intern Med 2002; 162: 2333–2341.
- 33 Ishikawa T, Hatakeyama K, Imamura T et al. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Circulation 2003; 91: 287–292.
